Cingulate Inc Cash Flow Conversion Efficiency
Cingulate Inc cash flow conversion efficiency. Based on the latest financial reports, Cingulate Inc (CING) has a cash flow conversion efficiency ratio of -1.434x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.60 Million) by net assets ($2.51 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Cingulate Inc (2019–2025)
Cash flow conversion efficiency of Cingulate Inc from 2019 to 2025. This chart illustrates how Cingulate Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Cingulate Inc stock price today for real-time trading data and today's change.
Cingulate Inc Cash Flow Conversion Ratio Explained
Cingulate Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Cingulate Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cingulate Inc ranked by their cash flow conversion efficiency. Also see CING company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
AurosTechnology Inc.
KQ:322310
|
0.037x |
|
Jetbest
TWO:4741
|
0.026x |
|
Hai Phong Hoang Ha Paper JSC
VN:HHP
|
N/A |
|
Gamma Nu Inc
KQ:192410
|
-0.167x |
|
Evertex Fabrinology Ltd
TW:1470
|
0.022x |
|
Nahar Poly Films Limited
NSE:NAHARPOLY
|
0.071x |
|
Malee Group Public Company Limited
BK:MALEE
|
0.047x |
|
Kingstate Electronics
TWO:3206
|
0.095x |
Annual Cash Flow Conversion Efficiency for Cingulate Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Cingulate Inc from 2019 to 2025. Review how financially flexible is Cingulate Inc to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $2.51 Million | $-17.25 Million | -6.874x | -177.73% |
| 2024-12-31 | $7.46 Million | $-18.45 Million | -2.475x | -213.08% |
| 2023-12-31 | $-6.87 Million | $-15.03 Million | 2.189x | +153.49% |
| 2022-12-31 | $3.88 Million | $-15.88 Million | -4.091x | -717.41% |
| 2021-12-31 | $20.84 Million | $-10.43 Million | -0.501x | +90.50% |
| 2020-12-31 | $1.29 Million | $-6.81 Million | -5.270x | +65.95% |
| 2019-12-31 | $615.88K | $-9.53 Million | -15.478x | -- |
About Cingulate Inc
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It … Read more